Phaseline

Targets › CLDN4

CLDN4 (Claudin-4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2030.

Can associate with other claudins to regulate tight junction structural and functional strand dynamics. May coassemble with CLDN8 into tight junction strands containing anion-selective channels that convey paracellular chloride permeability in renal collecting ducts (By similarity). (UniProt, O14493)

Open in Phaseline: the race on CLDN4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstellasASP1002
Anti-CLDN4 antibody-drug conjugate
CLDN4Phase 1Advanced Solid TumorsApr 2030

Conditions

Advanced Solid Tumors (1)

Modalities

mixed (1)

Companies

Astellas (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.